Longboard Pharmaceuticals, Inc. (LBPH)

NASDAQ: LBPH · IEX Real-Time Price · USD
3.09
0.00 (0.00%)
At close: Jun 29, 2022 11:41 AM
3.07
-0.02 (-0.65%)
After-hours: Jun 29, 2022 4:56 PM EDT
0.00%
Market Cap 53.20M
Revenue (ttm) n/a
Net Income (ttm) -31.70M
Shares Out 17.22M
EPS (ttm) -1.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 9,068
Open 3.11
Previous Close 3.09
Day's Range 3.01 - 3.11
52-Week Range 2.96 - 18.50
Beta n/a
Analysts Buy
Price Target 23.63 (+664.7%)
Earnings Date Aug 8, 2022

About LBPH

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which focuses on developing therapies for multiple neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Lo... [Read more...]

Industry Biotechnology
IPO Date Mar 12, 2021
Employees 21
Stock Exchange NASDAQ
Ticker Symbol LBPH
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for LBPH stock is "Buy." The 12-month stock price forecast is 23.63, which is an increase of 664.72% from the latest price.

Price Target
$23.63
(664.72% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Longboard Pharmaceuticals to Present at the JMP Securities 2022 Life Sciences Conference on June 15

SAN DIEGO, June 07, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurolog...

Longboard Pharmaceuticals to Participate in Five Upcoming Epilepsy-Focused Conferences this Summer

SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurolog...

Longboard Pharmaceuticals to Participate in Upcoming Investor Events

SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurologi...

Longboard Pharmaceuticals to Present Phase 1 Data for LP352 at the American Academy of Neurology Annual Meeting

SAN DIEGO, April 01, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurolo...

Longboard Pharmaceuticals to Participate in Cantor Fitzgerald's Virtual Rare Orphan Disease Summit

SAN DIEGO, March 23, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurolo...

Longboard Pharmaceuticals to Participate in Maxim Group 2022 Virtual Growth Conference

SAN DIEGO, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for...

Longboard Pharmaceuticals Announces the Appointment of Highly Accomplished Healthcare Executive Randall Kaye, M.D., a...

Philip Perera, M.D., to retire while continuing to participate as an advisor to Longboard Philip Perera, M.D., to retire while continuing to participate as an advisor to Longboard

Longboard Pharmaceuticals Provides Corporate Update and Reports Full Year 2021 Financial Results

SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) --  Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurol...

Longboard Pharmaceuticals, Inc. (LBPH) Could Find Support Soon, Here's Why You Should Buy the Stock Now

Longboard Pharmaceuticals, Inc. (LBPH) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revi...

Longboard Pharmaceuticals Appoints Life Sciences Executive Dr. Jane Tiller to Board of Directors

SAN DIEGO, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurolog...

Longboard Pharmaceuticals to Participate in Upcoming Investor Conferences

SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurolog...

Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2021 Financial Results

SAN DIEGO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurolog...

Longboard Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference on September 28, 2021

SAN DIEGO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurolo...

Longboard Pharmaceuticals Successfully Completes LP352 Multiple Ascending Dose Portion of Phase 1 Clinical Trial in H...

SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurolo...

Longboard Pharmaceuticals to Present at Two Upcoming Investor Conferences

SAN DIEGO, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurolog...

Longboard Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2021 Financial Results

SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurolog...

Longboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2021 Financial Results

SAN DIEGO, May 10, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, t...

Longboard Pharmaceuticals Announces Pricing of Initial Public Offering

SAN DIEGO, March 11, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases,...